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Conclusions. Our results indicate that renal cells produceEnhanced expression of complement C5a receptor mRNA in
C5aR and that activation of C5a/C5aR pathway on renal cellshuman diseased kidney assessed by in situ hybridization.
may be involved in tissue injury in mesGN.Background. Anaphylatoxin C5a mediates inflammatory re-
sponses through interaction with a specific C5a receptor (C5aR),
the expression of which is thought to be restricted to peripheral
blood leukocytes. Although the presence of C5aR on cultured Complement is one of the major mediators of inflam-
mesangial cells and tubular epithelial cells has recently been mation and tissue injury in immune-complex–mediated glo-
documented, the tissue distribution of C5aR in diseased kidney
merulonephritis. Complement activation occurs throughhas not yet been determined.
classic and alternative pathways, resulting in the releaseMethods. Immunohistochemistry and nonradioactive in situ
of anaphylatoxins or the formation of the terminal com-hybridization for C5aR were performed in 34 tissue samples
of kidneys from patients with various renal diseases, including plement components C5b-9. While the role of C5b-9 in
4 with minimal change nephrotic syndrome (MCNS), 5 with mem- the development of glomerulonephritis has been defined
branous nephropathy (MN), and 25 with mesangial prolifera- in various types of human and experimental models of
tive glomerulonephritis (mesGN; 15 patients with IgA nephropa- glomerulonephritis [1–3], the relative role of anaphyla-thy, 5 with non-IgA mesGN, and 5 with lupus nephritis). Normal
toxins remains obscure.portions of surgically resected kidney served as the control.
The anaphylatoxin C5a derived from the fifth comple-Results. In normal kidneys, C5aR protein was detected in tu-
ment component is composed of 74 amino terminalbular epithelial cells, while C5aR mRNA was detected in a
few glomerular cells, tubular epithelial cells, and vascular endo- amino acids of the C5  chain [4]. C5a is an important
thelial and smooth muscle cells. In MCNS, the distribution of mediator of the inflammatory response. On the develop-
C5aR protein and mRNA was similar to that in normal kidneys. ment of glomerulonephritis, it has been assumed that
In MN and mesGN, C5aR protein and mRNA were detected
the primary effects of C5a are mediated locally via direct/in mesangial cells, glomerular epithelial and endothelial cells,
indirect induction of cytokine synthesis, enhancementBowman’s capsule cells, tubular cells, infiltrating cells, and
of vascular permeability, attraction of phagocytes, andvascular endothelial and smooth muscle cells. The glomerular
expression of C5aR mRNA and protein correlated positively migration of neutrophils to the inflammatory sites in the
with the degree of mesangial hypercellularity and mesangial kidney [5]. C5a acts by binding to a specific, high-affinity
matrix expansion in mesGN. In the tubulointerstitium, intersti- C5a receptor (C5aR), which is a member of the rhodop-
tial expression of C5aR mRNA correlated positively with the de- sin family of G-protein–coupled receptors, and contains
gree of tubular atrophy and interstitial broadening in mesGN.
seven transmembrane segments [6]. Expression of theFurthermore, the interstitial expression of C5aR mRNA corre-
C5aR has been demonstrated in bone marrow-derivedlated positively with the level of serum creatinine.
cell lines [7], including neutrophils, macrophages and
monocytes, liver parenchymal cells [8], lung vascular
smooth muscles and endothelial cells, bronchial and alve-Key words: glomerulonephritis, inflammatory response, tissue injury,
immune-complex mediated glomerulonephritis, anaphylatoxin C5a. olar epithelial cells [8], and renal cells [8–11]. The expres-
sion of C5aR has been recently detected in the kidney
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presence of C5aR mRNA was confirmed by reverse tran- and grade 3 for macroscopic hematuria. The clinical pa-
rameters are summarized in Table 1.scriptase-polymerase chain reaction (RT-PCR) [9, 10].
These in vitro studies suggested that C5a exerts its dam-
Oligonucleotides and labelingaging effects on renal tissues via the expression of its
A 30 mer sequence of mRNA was selected for humanreceptor in these tissues and that activation of this recep-
C5aR. Antisense oligonucleotides for human C5aR cor-tor may play a role in the development of glomerulone-
responded to bases 52 to 81 of human C5aR [12]. Thephritis. More recently, using immunohistochemistry, the
selected sequence was significantly different from otherexpression of C5aR in proximal tubular epithelial cells
known sequences deposited in the latest release of thewas detected in normal human kidney [11]. To our
gene bank data (GenBank, Release 113, Septemberknowledge, however, the expression of C5aR and the
1999). The oligonucleotide was synthesized on an auto-cellular origin of the receptor in human diseased kidneys
matic DNA synthesizer (model 391, PCR-MATE EP;have not yet been clarified.
Applied Biosystems, Foster City, CA, USA) and wasIn the present study, we used immunohistochemistry
labeled using a digoxigenin (DIG) oligonucleotide tail-and nonradioactive in situ hybridization to examine
ing kit according to the current protocol (BoehringerC5aR in human normal and diseased kidneys. Our results
Mannheim Biochemica, Mannheim, Germany).
showed the presence of C5aR as well as C5aR mRNA
in the kidneys, and that the level of expression of C5aR In situ hybridization
mRNA correlated positively with the degree of tissue Nonradioactive in situ hybridization was performed
injury both in glomeruli and interstitium in human dis- according to a modified method developed in our labora-
eased kidneys. Our results indicate that renal cells pro- tory [13]. In brief, the specimens were cut to a thickness
duce C5aR and that the C5a/C5aR pathway may be a of 4 m and were placed on glass slides coated with
candidate for inducing tissue injury. It is also suggested 3-aminopropyltriethoxysilane (A3684; Sigma, St. Louis,
that the effect of complement activation on tissue injury MO, USA). The sections were fixed with 4% paraformal-
is not only through the formation of C5b-9, but also dehyde in phosphate-buffered saline (PBS) and then de-
through the anaphylatoxin C5a in both glomeruli and proteinized using HCl and proteinase K (Sigma P-4914).
interstitium in human glomerulonephritis. After prehybridization, the sections were hybridized with
DIG-labeled oligonucleotide probe in the prehybridiza-
tion buffer. After washing with 0.075% BRIJ (Sigma 430
METHODS AG-6) in 2 and 0.5 standard saline citrate (SSC) at
Kidney tissues room temperature, sections were stained immunohisto-
chemically to visualize the hybridized DIG-labeled probeA total of 34 renal biopsy specimens from 34 patients
using mouse monoclonal anti-DIG antibody (Boehringerwith renal diseases were examined, including nonpro-
Mannheim Biochemica), horseradish peroxidase (HRP)-liferative [4 patients with minimal-change nephrotic syn-
conjugated rabbit anti-mouse antibody (Dako P260; Da-drome (MCNS) and 5 patients with membranous nephrop-
kopatts, Glostrup, Denmark) and HRP-conjugated swineathy (MN)] and mesangial proliferative glomerulonephritis
anti-rabbit antibody (Dako P399) successively. Color[mesGN; 15 patients with IgA nephropathy (IgAN), 5
was developed by reaction with H2O2 and diaminobenzi-patients with non-IgA mesGN (non-IgAN), and 5 pa-
dine tetrahydrochloride. Finally, sections were counter-tients with lupus nephritis (WHO Class IIb (LN)]. None
stained with methyl green and were mounted. Cellsof the patients were treated with steroids or immunosup-
clearly stained in the cytoplasm or stained with a perinu-pressive drugs before renal biopsy. Five tissue specimens
clear pattern were identified as C5aR mRNA-positive
from uninvolved areas of adenocarcinomatous kidneys
cells. On the other hand, cells with nuclei stained with
served as normal controls. Each patient gave an informed methyl green alone were considered negative for C5aR
consent to renal biopsy and the present study. Diagnosis mRNA.
of renal disease was based on clinical, light microscopic, Two observers, independently and without the prior
immunofluorescence, and electron microscopic findings. knowledge of clinical and laboratory data, examined the
Samples were frozen in O.C.T. compound (Miles Inc., tissues histologically and evaluated the expression of
Elkhardt, IN, USA) and were stored at 80C until use. C5aR mRNA in each biopsy. For semiquantitative histo-
The following laboratory parameters were determined logic grading of the glomeruli, after color development
at the time of biopsy: age, gender, proteinuria, hematu- of immunohistochemistry, sections were stained by peri-
ria, and the level of serum creatinine. The severity of odic acid-Schiff (PAS) reaction, which allowed the iden-
hematuria was graded as follows: 0 0 to 5 erythrocytes tification of histologic changes such as mesangial expan-
per high-power field; 1  5 to 30 erythrocytes per high- sion. PAS staining also allowed identification of the exact
location of those cells positive for C5aR mRNA relativepower field; 2  30 erythrocytes per high-power field;
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Table 1. Clinical characteristics of patients enrolled in this study
IF
Age Serum creatinine Urinary protein Grade of
No. Sex years Diagnosis mg/dL g/24 h hematuriaa C3b IgGb
1 M 26 MCNS 0.8 4.7 0  
2 F 15 MCNS 0.7 7.4 0  
3 M 20 MCNS 0.6 6.6 0  
4 F 22 MCNS 0.7 4.4 0  
5 F 60 MN 0.9 1.1 2 3	 2	
6 M 54 MN 0.8 2.5 1 2	 	
7 M 52 MN 0.9 2.2 1 3	 	
8 M 63 MN 0.9 1.4 1 3	 3	
9 M 46 MN 0.9 1.5 1 3	 2	
10 F 21 IgAN 0.6 0.7 3 2	 	
11 M 21 IgAN 0.9 1.4 3 	 	
12 M 47 IgAN 1.0 0.7 2 	 3	
13 F 24 IgAN 0.7 0.1 3 2	 	
14 M 23 IgAN 1.0 1.2 3 	 	
15 F 46 IgAN 0.9 0.2 2 	 3	
16 F 21 IgAN 0.6 0.1 3 	 	
17 F 44 IgAN 0.9 0.7 3 	 	
18 F 39 IgAN 1.0 0.2 0 	 	
19 F 39 IgAN 0.6 0.2 3 	 3	
20 M 35 IgAN 1.0 1.2 3 	 2	
21 M 56 IgAN 1.5 0.4 2 	 	
22 M 51 IgAN 1.5 5.3 2  	
23 M 44 IgAN 1.5 0.9 3 3	 2	
24 F 20 IgAN 0.6 0.4 3 2	 2	
25 F 44 Non-IgAN 3.3 8.1 3 2	 2	
26 F 42 Non-IgAN 1.0 0.4 3 	 	
27 M 46 Non-IgAN 2.0 1.3 3  
28 M 44 Non-IgAN 1.5 0.5 3  
29 M 35 Non-IgAN 1.5 0.3 3 	 
30 M 45 LN 1.7 0.8 2 2	 	
31 F 28 LN 0.8 0.6 3 3	 	
32 M 54 LN 0.8 2.5 1 3	 3	
33 F 48 LN 0.8 1.5 0 	 	
34 F 33 LN 0.5 1.5 3 2	 2	
Abbreviations are: M, male; F, female; IF; immunofluorescence microscopy; MCNS, minimal change nephrotic syndrome; MN, membranous nephropathy; IgAN,
IgA nephropathy; LN; lupus nephritis.
a The severity of hematuria was graded as described in the Methods section
b Semiquantitative assessment of staining was: , no staining; intensity of staining was graded from  to 3	
to the glomerular basement membrane and mesangial tative interstitial fields, as described previously [15]. In
each field, tubulointerstitial change, tubular atrophy, andarea. The cells were identified as mesangial cells within
the PAS-positive mesangial matrix and glomerular epi- interstitial broadening were graded separately using a
0 to 3	 scale as described previously in this article.thelial cells on the capillary basement membrane.
Since the degree of glomerular injury is heterogeneous After determining the degree of glomerular and tubu-
lointerstitial injury, in the same glomeruli and interstitialamong glomeruli during the progression of glomerulo-
nephritis, it is possible that the level of expression of C5aR fields, semiquantitation of the expression of C5aR mRNA
was performed. The numbers of immunoreactive cellsmRNA may relate to the degree of glomerular injury in
each glomerulus. Hence, we evaluated the degree of in renal tissues were scored separately relative to the
total number of glomerular cells, mesangial cells andglomerular injury as well as expression of each C5aR
mRNA in each glomerulus rather than averaging the glomerular epithelial cells, tubules, and interstitium ac-
cording to the following scheme, as described previouslyinjury in each section. In this study, five to seven glomer-
uli, each with an equatorial plane cross-section, were [16], with some modification: 0  no positive cells; 1 
scattered single positive cells in a focal distribution; 2 analyzed in each section. Mesangial hypercellularity and
mesangial matrix expansion were graded separately us- diffusely scattered positive cells; and 3 numerous posi-
tive cells, frequently in clusters.ing a 0 to 3	 scale (absent or minimal, mild, moderate,
and marked) according to methods described previously To evaluate the specificity of the signals for C5aR
mRNA, we performed three control experiments, includ-[14]. In the tubulointerstitium, we examined three to five
fields of the cortical interstitium in each section under ing pretreatment of RNase, a study with a sense probe
and a competitive study, as described previously [17, 18].a low magnification (100) and analyzed three represen-
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Fig. 1. In situ hybridization study for C5aR
mRNA (A, C, and E) and immunohistochem-
istry for C5aR protein (B, D, and F ) in renal
sections of control kidney. Note the weak
C5aR mRNA signals, particularly in glomeru-
lar epithelial cells and cells of Bowman’s cap-
sule (A, arrowheads). Note also the lack of
C5aR protein in the glomeruli of the control
kidney (B). C5aR mRNA is expressed in tubu-
lar epithelial cells (C, arrowheads), vascular
endothelial cells, and smooth muscle cells (E).
C5aR protein is also present in tubular epithe-
lial cells (D), vascular endothelial cells, and
smooth muscle cells (F). Magnification 200.
Immunohistochemistry cance using one-way analysis of variance (ANOVA) with
Scheffe’s F test. Correlations between two variables wereSections from frozen kidney tissues were reacted with
tested for significance using the Spearman’s rank correla-a monoclonal antibody against CD88 (Serotec, Oxford,
tion test. A P value less than 0.05 was considered statisti-UK) to identify human C5aR. A monoclonal antibody
cally significant.against CD 68 (M718 Dako; Dakopatts) was also used
to identify any infiltrating monocytes and macrophages.
After reacting with the first antibodies, the same sections RESULTS
were reacted with HRP-conjugated rabbit anti-mouse
C5aR mRNA and C5aR protein in normal kidneysimmunoglobulin and HRP-conjugated swine anti-rabbit
Glomeruli. In situ hybridization showed the presenceimmunoglobulin, as described in the procedure of in
of a weak but significant signal for C5aR mRNA in mes-situ hybridization. Mouse IgG1 was used as a negative
angial cells, cells of Bowman’s capsule, and glomerularcontrol (Dako X931; Dakopatts) instead of monoclonal
epithelial cells (Fig. 1A). However, no positive immuno-antibodies. The number of CD88-positive cells in renal
staining for C5aR protein was observed in the glomerulustissues was scored as described for the in situ hybridiza-
(Fig. 1B).tion procedure.
Interstitium. C5aR mRNA was observed in some tubu-
Statistical analysis lar epithelial cells (Fig. 1C), vascular endothelial (Fig. 1E),
and smooth muscle cells (Fig. 1E) in the interstitium ofData were expressed as mean  SD. Differences be-
tween different groups were tested for statistical signifi- the normal control tissue. Consistently, immunohisto-
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Table 2. Expression of C5aR mRNA in normal and
diseased kidneys







Data are mean  SD. Abbreviations are in Table 1.
a In each glomerulus, the degree of C5aR mRNA was scored according to the
method of Niemir et al [16], with a minor modification. Five to seven glomeruli
in each section were analyzed. Cells containing clearly stained cytoplasm were
identified as C5aR mRNA and protein-positive cells. Differences between groups
were tested for statistical significance using one-way ANOVA with Scheffe’s F
test.
b P 
 0.01 vs. control kidney
Fig. 3. Immunohistochemistry for C5aR protein in glomeruli of pa-
tients with IgA nephropathy (A) and LN (B). C5aR is present in mesan-
gial cells, glomerular epithelial cells, glomerular endothelial cells, and
cells of Bowman’s capsule. Magnification 200.
were higher than in the control (Table 2). Overexpres-
sion of C5aR mRNA was observed mainly in mesangial
cells within the PAS-positive mesangial matrix in
Fig. 2. In situ hybridization study for C5aR mRNA in sections of pa- mesGN. Marked expression was noted in areas of mesan-
tients with minimal change nephrotic syndrome (MCNS; A), membra- gial proliferation (Fig. 2C–F). The degree of expressionnous nephropathy (MN; B), IgA nephropathy (IgAN; C, mild lesion;
of C5aR mRNA in mesangial cells was higher than thatD, severe lesion), and lupus nephropathy (LN; E ). In situ hybridization
followed by PAS staining in IgA nephropathy (F–H ). Note the expres- in glomerular epithelial cells in mesGN (Table 3). In
sion of C5aR mRNA in mesangial cells (F, arrow), glomerular epithelial MN, mainly glomerular epithelial cells were positive forcells (G, arrowheads), cells of Bowman’s capsule (H, arrowheads), and
C5aR mRNA (Fig. 2B). The degree of C5aR mRNAglomerular endothelial cells (H, arrow). Magnification A–E,200; F–H,
400. expression in glomerular epithelial cells was higher than
in mesangial cells (Table 3). Some glomerular epithelial
cells on the capillary basement membrane, cells of Bow-
man’s capsule, and glomerular endothelial cells were also
chemical study showed the presence of C5aR protein in positive for C5aR mRNA (Fig. 2G, H). Immunostaining
tubular epithelial cells (Fig. 1D) and vascular endothelial for C5aR was observed mainly in mesangial cells in IgAN
(Fig. 1F) and smooth muscle cells (Fig. 1F). (Fig. 3A), non-IgAN, and LN (Fig. 3B). Some glomerular
epithelial cells, cells of Bowman’s capsule, and glomeru-
C5aR mRNA and C5aR protein in diseased kidneys lar endothelial cells were positive for C5aR protein
Glomeruli. In MCNS, a weak but significant staining (Fig. 3). The level of C5aR mRNA expression correlated
for C5aR mRNA was present in the glomeruli (Fig. 2A), significantly with the degree of mesangial hypercellular-
but C5aR protein was not observed similar to the control ity and mesangial matrix expansion in mesGN (Table 4).
sections (data not shown). However, in MN and mesGN, Furthermore, glomerular expression of C5aR protein
including IgAN, non-IgAN, and LN, a large number of correlated with the degree of mesangial hypercellularity
cells were positive for C5aR mRNA (Fig. 2B–E). The and mesangial matrix expansion (Table 4).
Interstitium. In MCNS, the signal for C5aR mRNA waslevels of C5aR mRNA expression in MN and mesGN
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Table 4. Correlation between C5aR mRNA and protein expressionTable 3. Expression of C5aR mRNA in mesangial cells and
glomerular epithelial cells in mesGN and MN and degree of tissue injury in patients with mesangial proliferative
glomerulonephritis (mesGN)
C5aR mRNA C5aR mRNA
expression in mesangial expression in epithelial C5aR mRNAc C5aR proteinc
Diagnosis cell/glomerulusa cell/glomerulusa
Mesangial hypercellularitya 0.724d 0.791d
Mesangial matrix expansiona 0.837d 0.632eIgAN 2.830.83b 1.330.59
Non-IgAN 2.500.51b 1.280.46 Tubular atrophyb 0.865d 0.410
Interstitial broadeningb 0.889d 0.327LN 2.890.32 2.670.23
MN 1.050.25 2.220.43b a The degrees of mesangial hypercellularity and mesangial matrix expansion
were graded from 0 to 3 according to the method of Yoshioka et al [14]; five toData are mean  SD. Abbreviations are in Table 1.
seven glomeruli in each section were analyzed.a In each glomerulus, the degree of C5aR mRNA in mesangial and glomerular
b The degrees of tubular atrophy and interstitial broadening were gradedepithelial cells was scored separately according to the method of Niemir et al
separately from 0 to 3 according to the method of Furusu et al [15]; three to[16], with a minor modification: 0 no positive cells; 1 scattered single positive
five interstitial fields in each section were analyzed.cells; 2  diffusely scattered positive cells; and 3  numerous positive cells. Five
c In each glomerulus and tubulointerstitial field, the degrees of C5aR mRNAto seven glomeruli in each section were analyzed. Cells containing clearly stained
and protein staining were scored according to the method of Niemir et al [16]cytoplasm were identified as C5aR mRNA-positive cells. The cells were identified
with a minor modification. Cells containing clearly stained cytoplasm were identi-as mesangial cells within the PAS-positive mesangial matrix and glomerular
fied as C5aR mRNA and protein-positive cells. Tabular entries are Spearman’sepithelial cells on the capillary basement membrane. Difference between the
correlation coefficients.C5aR mRNA score in mesangial cells and in glomerular epithelial cells was
d P 
 0.01, e P 
 0.05tested for statistical significance using one-way analysis of variance with Scheffe’s
F test.
b In IgAN and non-IgAN, the C5aR mRNA expression in mesangial cells is
higher than in glomerular epithelial cells; in contrast, in MN, the C5aR mRNA
score in glomerular epithelial cells is higher than in mesangial cells (P 
 0.05)
level of serum creatinine (P 
 0.05). However, there
was no correlation between the expression of C5aR
mRNA and the extent of C5aR protein expression and
detected in tubular epithelial cells, vascular endothelial any other clinical parameters in mesGN. In MN, none
cells, and vascular smooth muscle cells. C5aR protein of the clinical parameters correlated with the level of
was detected in tubular epithelial cells (data not shown). C5aR mRNA expression among total glomerular cells,
In MN and mesGN, C5aR mRNA was expressed in tu- mesangial cells, glomerular epithelial cells, and in tubulo-
bular epithelial cells (Fig. 4A), vascular endothelial cells interstitial area or with C5aR protein expression.
(Fig. 4B), and vascular smooth muscle cells (Fig. 4B).
The signal was particularly strong in the cells of atrophic Evaluation of the specificity of immunohistochemistry
and in situ hybridizationtubules (Fig. 4C). In areas of severe interstitial expan-
sion, some infiltrating cells were also positive for C5aR No staining was detected in any specimens when mouse
mRNA (Fig. 4D). A proportion of these cells was stained IgG1 was used as a negative control instead of mono-
for C5aR protein (Fig. 5). The number of C5aR mRNA- clonal antibodies in the immunohistochemical studies
positive tubules correlated significantly with the degree (data not shown). The specificity of the signal for C5aR
of tubular atrophy in mesGN (Table 4). The number of mRNA was evaluated by three control experiments.
interstitial infiltrating cells positive for C5aR mRNA also When a 100-fold excess of unlabeled antisense oligonu-
correlated with the degree of interstitial broadening (Ta- cleotide was added to the standard hybridization mixture
ble 4). However, the extent of staining for C5aR protein containing DIG-labeled C5aR antisense, the signal was
in tubules and infiltrating cells did not correlate with the completely abolished (Fig. 6). An in situ hybridization
tubulointerstitial changes (Table 4). study was also performed with a DIG-labeled C5aR
sense probe and pretreatment of tissue with RNase. No
Relationship between the expression of C5aR and
signal for C5aR mRNA was detected in these control
C3 deposition
experiments (data not shown).
In mesGN, the expression of C5aR mRNA and protein
did not correlate with the degree of C3 deposition in
DISCUSSIONglomeruli.
Our study identified the type of cells that produce
Relationships between the expression of C5aR and C5aR mRNA in human kidney. These include mesangial
clinical parameters cells, glomerular epithelial and endothelial cells, cells
of Bowman’s capsule, tubular epithelial cells, vascularWe also examined the relationships between propor-
tions of C5aR mRNA-positive cells among total glomer- endothelial and smooth muscle cells, and infiltrating
cells. These results also confirm the presence of C5aRular cells, mesangial cells, glomerular epithelial cells,
tubules, and interstitium and protein expression in these protein in human kidney. Furthermore, we show that
the level of C5aR mRNA expression increase with thecells, and various clinical parameters in patients with
mesGN and MN. In mesGN, the degree of expression progression of renal tissue injury in human mesGN.
Since C5aR is expressed on the surface of circulatingof C5aR mRNA in the interstitium correlated with the
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Fig. 4. In situ hybridization study for C5aR
mRNA in the interstitium of IgA nephropa-
thy. Tubular epithelial cells positive for C5aR
mRNA (A). C5aR mRNA is expressed on
vascular endothelial cells (B, arrowheads) and
vascular smooth muscle cells (B, arrows).
C5aR mRNA is strongly expressed in epithe-
lial cells of atrophic tubules (C ). Some infil-
trating cells are positively stained for C5aR
mRNA (D, arrowheads). Magnification A and
C, 250; B and D, 200.
Fig. 5. Immunohistochemistry for C5aR in
the interstitium of IgA nephropathy. Note the
presence of C5aR protein in tubular epithelial
cells (A, arrowheads), vascular endothelial
cells (B, arrowheads), and vascular smooth
muscle cells (B, arrows). Magnification 200.
Fig. 6. Competitive study for the specificity
of C5aR mRNA signals. C5aR mRNA-posi-
tive signals are detected in the glomerulus (A,
arrowheads). The section hybridized with the
C5aR antisense probe in the presence of a 100-
fold excess of unlabeled C5aR homologous
oligonucleotides. Note the complete disap-
pearance of signals for C5aR mRNA (B).
Magnification 200.
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peripheral blood cells, including monocytes/macrophages, area in humans [2, 28] and animal models [29] of glomer-
ulonephritis, C5a, which is generated during complementneutrophils, and leukocytes [19], we examined the contri-
bution of these cells to C5aR mRNA-positive cells found activation, may be involved in mediating tubulointersti-
tial injury via tubulointerstitial expression of its receptor.in the glomeruli by searching for CD68 (a marker of
monocytes)-positive cells among the C5aR mRNA-posi- C5a can stimulate the release of cytokines and chemo-
kines from mesangial cells [9] and inflammatory cellstive intraglomerular cells. In fact, immunostaining of
monocytes was also detected in glomeruli (data not [30, 31]. It is possible that C5a may have a similar effect
on tubular epithelial cells. In fact, tubular epithelial cellsshown). Moreover, we carefully examined the presence
of neutrophils in glomeruli morphologically, and some can produce a variety of cytokines [for example, interleu-
kin-6 (IL-6) [32] and tumor necrosis factor- (TNF-)infiltration of neutrophils was observed. These findings
suggest that some infiltrating cells into glomeruli may [33]] and chemokines [IL-8 [34], monocyte chemoattrac-
tant protein-1 (MCP-1) [35], and RANTES [36]]. In addi-be relevant to C5aR expression; however, the number
of these cells was clearly far less than that of C5aR tion, C5a binding to C5aR leads to an up-regulated ex-
pression of adhesion molecules in endothelial cells andmRNA-positive glomerular cells. This observation sug-
gests that the large quantity of C5aR in glomeruli is margination of inflammatory cells on pulmonary vessels
during complement activation in vivo [37–39]. This evi-derived primarily from glomerular cells rather than infil-
trating monocytes or macrophages. dence suggests that C5a may up-regulate the chemotaxis
and attraction of interstitial infiltrating cells by bindingThe present study demonstrates that the glomerular
expression of C5aR in glomerular cells correlates posi- to locally synthesized C5aR and that the interaction of
C5a/C5aR in tubulointerstitium may influence the pro-tively with the degree of mesangial hypercellularity and
mesangial matrix expansion in mesGN. Deposition of the gression of tubulointerstitial injury.
Immunohistochemical staining in the present studyterminal complement components, C5b-9, clearly plays
a major role in glomerular cell proliferation and the failed to demonstrate the expression of C5aR in the glo-
meruli of normal kidneys and MCNS, although C5adevelopment and progression of glomerular sclerosis
[20, 21]. This finding suggests that the interaction be- mRNA was expressed in glomerular cells. This different
expression pattern suggests that either the level of basaltween C5a and C5aR on the renal cells also may play a
role in this process. In fact, C5a can induce proliferation glomerular expression of C5aR protein in normal kidney
and MCNS in vivo is below the level of detection byof cultured human mesangial cells [9] and enhances the
release of platelet-derived growth factor [9], which is a immunohistochemistry or that up-regulation of C5aR
expression may occur in mesGN or MN. The mediatorsknown mediator of mesangial proliferation and matrix
expansion from mesangial cells. In addition, it is also responsible for C5aR up-regulation in renal cells are
not yet known. Previous studies identified TNF- as anpossible that C5a may alter glomerular blood flow by
directly binding to C5aR because C5a causes smooth essential mediator of C5aR expression in mouse brain
[40]. Furthermore, interferon- (INF-), an importantmuscle contraction and mediates changes in both vascu-
lar tone and permeability [22]. Since mesangial cells are immunoregulatory cytokine that is produced in glomeru-
lonephritis [41], also stimulates the synthesis of C5aR inthought to be derived from vascular smooth muscle cells
[23–25], it is possible that the interaction of C5a/C5aR human myeloblastic cells [42]. However, the mediator(s)
responsible for inducing C5aR expression in renal cellscauses mesangial cell contraction. Related to this effect,
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